A new industry focus has emerged on sterilization as biomanufacturing scales—arguing that steam-in-place systems remain a major constraint on capacity, cost, and plant siting even as single-use technology reduces other bottlenecks. The analysis highlights the infrastructure burden of conventional aseptic design, including hygienic piping and boiler capacity, and notes the time and operational complexity of maintaining sterility at commercial scale. It also positions sterilization as a renewed R&D area amid tighter margins. Several alternative approaches are being explored, including ultraviolet radiation, vaporized hydrogen peroxide, chlorine-dioxide gas, ozone, and supercritical carbon dioxide. Biosphere, the example cited, is developing a reactor architecture using UV to reduce dependence on steam piping and fluid sterilization energy. For biotech operators, the development path could shift by improving how quickly and reliably large-scale aseptic systems can be designed, validated, and commissioned—an operational lever distinct from upstream strain or process engineering.